News Picture Generic

Implementation of Large-Scale Multi-Reactor Automation for Process Development

April 14, 2026

Helvetica Chimica Acta

Pharmaceuticals increasing complexity requires longer synthesis with unique processes for each step, increasing the number of experiments to develop robust sustainable processes. The time to develop these processes is getting shorter, and automation can support the growing need to efficiently perform more experiments. Automation reaction screening focuses more on small- scale high-throughput experimentation (HTE), which may not be applicable for late phase process development. To support these activities and decrease development time, we describe the implementation of a flexible large-scale multi-reactor automation platform for process development.

For details: 

Implementation of Large-Scale Multi-Reactor Automation for Process Development

Andreas Kaegi, Markus Spaeti, Jarred Blank

Chemical & Analytical Development, Novartis Pharma, Basel, Switzerland

Helvetica Chimica Acta
https://onlinelibrary.wiley.com/doi/abs/10.1002/hlca.202500120

Contact us to learn more about this exciting article:https://www.chemspeed.com/contact/

Other Recent News

Discover more news articles you might be interested in

Read more about Identifying critical powder properties for high-throughput dispensing of alumina and organic templates
News Picture 1 1 V2
Jun
16

Identifying critical powder properties for high-throughput dispensing of alumina and organic templates

Screening powder properties such as flowability, compressibility, and particle geometry is crucial for controlling ceramic processing, particularly in automated workflows that demand high reproducibility. Sacrificial templating for porous ceramics is well suited to automation because it is prone to variability arising from manual handling.

Read more about Integration of Machine Learning and Automated Synthesis for Accelerated Drug and Material Research
News Picture 1 1 V2
Jun
2

Integration of Machine Learning and Automated Synthesis for Accelerated Drug and Material Research

The challenges posed by global climate change and disease risks have intensified the demand for efficient and practical materials and molecules. Traditional trial-and-error approaches are becoming increasingly inefficient and resource-intensive. The rapid advancement of artificial intelligence (AI) has opened new avenues to accelerate research and shorten development cycles.

© Chemspeed Technologies 2026